Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kieron Dunleavy

Showing results (51-60 of 130) with videos related to

Pageof 13
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 17, 2014
Precision treatment of distinct molecular subtypes of diffuse large B-cell lymphoma: ascribing treatment based on the molecular phenotypeKieron Dunleavy, Mark Roschewski, Wyndham H Wilson
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 15, 2020
Reply to M. Hertzberg et alMark Roschewski, Kieron Dunleavy, Wyndham H Wilson
Leukemia & Lymphoma|November 6, 2009
Targeting HLA-DRKevin Tay, Kieron Dunleavy, Wyndham H Wilson
The New England Journal of Medicine|July 19, 2013
Therapy in primary mediastinal B-cell lymphomaWyndham H Wilson, Cliona Grant, Kieron Dunleavy
Blood|December 21, 2014
FDG PET-CT in follicular lymphoma: a case-based evidence reviewStephen D Smith, Mary Redman, Kieron Dunleavy
Leukemia & Lymphoma|January 21, 2014
Moving beyond rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone for diffuse large B-cell lymphomaMark Roschewski, Kieron Dunleavy, Wyndham H Wilson
Blood Reviews|February 16, 2010
Novel agents for B-cell non-Hodgkin lymphoma: science and the promiseKevin Tay, Kieron Dunleavy, Wyndham H Wilson
International Journal of Hematology|October 23, 2012
Diffuse large B cell lymphoma: molecular targeted therapyMark Roschewski, Kieron Dunleavy, Wyndham H Wilson
Hematology/Oncology Clinics of North America|November 28, 2016
Update on Burkitt LymphomaKieron Dunleavy, Richard F Little, Wyndham H Wilson
Blood|March 24, 2006
The case for rituximab in AIDS-related lymphomaKieron Dunleavy, Wyndham H Wilson, Lawrence D Kaplan
Pageof 13

Showing results (51-60 of 130) with videos related to

Sort By:
Pageof 13
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 17, 2014
Precision treatment of distinct molecular subtypes of diffuse large B-cell lymphoma: ascribing treatment based on the molecular phenotypeKieron Dunleavy, Mark Roschewski, Wyndham H Wilson
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 15, 2020
Reply to M. Hertzberg et alMark Roschewski, Kieron Dunleavy, Wyndham H Wilson
Leukemia & Lymphoma|November 6, 2009
Targeting HLA-DRKevin Tay, Kieron Dunleavy, Wyndham H Wilson
The New England Journal of Medicine|July 19, 2013
Therapy in primary mediastinal B-cell lymphomaWyndham H Wilson, Cliona Grant, Kieron Dunleavy
Blood|December 21, 2014
FDG PET-CT in follicular lymphoma: a case-based evidence reviewStephen D Smith, Mary Redman, Kieron Dunleavy
Leukemia & Lymphoma|January 21, 2014
Moving beyond rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone for diffuse large B-cell lymphomaMark Roschewski, Kieron Dunleavy, Wyndham H Wilson
Blood Reviews|February 16, 2010
Novel agents for B-cell non-Hodgkin lymphoma: science and the promiseKevin Tay, Kieron Dunleavy, Wyndham H Wilson
International Journal of Hematology|October 23, 2012
Diffuse large B cell lymphoma: molecular targeted therapyMark Roschewski, Kieron Dunleavy, Wyndham H Wilson
Hematology/Oncology Clinics of North America|November 28, 2016
Update on Burkitt LymphomaKieron Dunleavy, Richard F Little, Wyndham H Wilson
Blood|March 24, 2006
The case for rituximab in AIDS-related lymphomaKieron Dunleavy, Wyndham H Wilson, Lawrence D Kaplan
Pageof 13